September 12, 2018

“Twitter Isn’t Just for Millennials.”

How one hematologist learned to use and value it

smart-phone_650x450

Using Twitter was not his idea. But after being inspired by peers who were live-tweeting at the 2014 American Society of Hematology Annual Meeting, Cleveland Clinic hematologist Aaron Gerds, MD, has learned that “Twitter isn’t just for millennials.”

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Since then, he’s discovered how Twitter can help him save time in keeping up with the latest developments in his specialty, myeloproliferative neoplasms (MPN). (He follows hematologists, patients and advocacy groups that tweet with the hashtag #MPNSM.) And he’s opened a new line of communication with patients who follow him @AaronGerds.

He shares his perspectives — including tips for physicians nervous about signing up for a Twitter account — in ASH Clinical News.

Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-CNR-4274330-CQD-Hero-650×450
October 18, 2023
Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

23-CNR-4185077-CQD-Hero-650×450
August 31, 2023
CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

outreach to underserved communities
June 2, 2023
Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust

Ad